SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
Rhea-AI Summary
SIGA Technologies (NASDAQ: SIGA), a commercial-stage pharmaceutical company, has scheduled a business update conference call and webcast for August 5, 2025, at 4:30 PM ET. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire discussing the company's second-quarter 2025 results.
Investors can access the call through a domestic dial-in (1-800-717-1738) or international dial-in (1-646-307-1865). A replay will be available for two weeks, and the webcast will be accessible through SIGA's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – SIGA
In the trading session that priced this news, SIGA declined 2.77%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.
A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time.
Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers.
A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website.
About SIGA
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit www.siga.com.
Contacts:
Suzanne Harnett
sharnett@siga.com
and
| Investors | Media |
| Jennifer Drew-Bear, Edison Group Jdrew-bear@edisongroup.com | Holly Stevens, CG Life hstevens@cglife.com |
